The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 09, 2019

Filed:

Aug. 21, 2015
Applicant:

Academia Sinica, Taipei, TW;

Inventors:

Chi-Huey Wong, Rancho Santa Fe, CA (US);

Chung-Yi Wu, New Taipei, TW;

Assignee:

ACADEMIA SINICA, Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 5/02 (2006.01); C07H 5/04 (2006.01); C07H 5/06 (2006.01); A61K 39/00 (2006.01); C07H 15/04 (2006.01); C07H 15/26 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); C08B 37/00 (2006.01); A61K 31/715 (2006.01); A61K 31/7028 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 31/7028 (2013.01); A61K 31/715 (2013.01); C07H 5/02 (2013.01); C07H 5/04 (2013.01); C07H 5/06 (2013.01); C07H 15/04 (2013.01); C07H 15/26 (2013.01); C07K 16/3076 (2013.01); C07K 16/44 (2013.01); C08B 37/006 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/627 (2013.01);
Abstract

The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.


Find Patent Forward Citations

Loading…